Study of Pharmacokietics of tritium-labeled Kagocel

Introduction. The pharmaceutical substance Kagocel is the active substance of the drug of the same name, which is used to treat viral infections. The method using tritium as a radioactive label is most appropriate to study the pharmacokinetics of this high-polymer compound in animal experiments. Objective: to perfect a bioanalytical procedure for detecting kagocel in animals and determining the main features of the pharmacokinetics of this polymer substance. Material and methods. Pharmacokinetic studies were conducted using the tritium-labeled Kagocel substance in Wistar rats. The investigation quantified the level of kagocel in the blood, tissues, and excreta of the animals. Results. The possibility of studying the pharmacokinetics of kagocel, by using the solutions of tritium-labelled substance was experimentally confirmed. The investigators determined the main pharmacokinetic parameters that were used to establish that kagocel is the typical polymer substance with a relatively low (13 -15%) absolute bioavailability when administered orally. Kagocel was characterized by its long (about 2-day) half-life and without substantial accumulation in organs and tissues. The investigators also established some methodological features of using tritium-labeled modified polysaccharides, which should be taken into account when validating the bioanalytical procedures for controlling the distribution and excretion of such products. Conclusion. The methodological approaches applied in this investigation allow quantification of the level of tritium-labeled kagocel in biological matrices. Additional studies are needed to clarify a number of parameters that more fully characterize the ADME processes of the polymer kagocel.

kagocel, polymer, pharmacokinetics, tritium, label